Brokerages forecast that CytomX Therapeutics (NASDAQ:CTMX) will announce earnings per share of ($0.30) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for CytomX Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.60). CytomX Therapeutics reported earnings per share of ($0.23) in the same quarter last year, which would indicate a negative year-over-year growth rate of 30.4%. The company is expected to announce its next quarterly earnings results on Friday, May 4th.
On average, analysts expect that CytomX Therapeutics will report full year earnings of ($1.44) per share for the current financial year, with EPS estimates ranging from ($2.85) to ($0.41). For the next fiscal year, analysts expect that the firm will post earnings of ($2.07) per share, with EPS estimates ranging from ($4.22) to ($1.09). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for CytomX Therapeutics.
CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Wednesday, March 7th. The biotechnology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.43) by $0.45. The firm had revenue of $27.07 million for the quarter, compared to the consensus estimate of $10.70 million. CytomX Therapeutics had a negative net margin of 60.17% and a negative return on equity of 71.42%.
In other news, CFO Debanjan Ray sold 33,000 shares of CytomX Therapeutics stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $29.99, for a total value of $989,670.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Rachel Humphrey sold 23,840 shares of CytomX Therapeutics stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $30.00, for a total transaction of $715,200.00. Following the completion of the sale, the insider now owns 54,074 shares in the company, valued at $1,622,220. The disclosure for this sale can be found here. Insiders sold 103,548 shares of company stock worth $3,101,686 over the last quarter. 8.00% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of Montreal Can acquired a new stake in shares of CytomX Therapeutics in the fourth quarter valued at approximately $124,000. Macquarie Group Ltd. acquired a new stake in shares of CytomX Therapeutics in the third quarter valued at approximately $107,000. MetLife Investment Advisors LLC acquired a new stake in shares of CytomX Therapeutics in the fourth quarter valued at approximately $245,000. Virtus Fund Advisers LLC acquired a new stake in shares of CytomX Therapeutics in the fourth quarter valued at approximately $339,000. Finally, Alambic Investment Management L.P. acquired a new stake in shares of CytomX Therapeutics in the fourth quarter valued at approximately $355,000. Institutional investors own 78.07% of the company’s stock.
Shares of CTMX stock opened at $28.61 on Friday. CytomX Therapeutics has a 52 week low of $13.00 and a 52 week high of $35.00.
ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate CytomX Therapeutics (CTMX) to Announce -$0.30 Earnings Per Share” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2018/04/16/zacks-brokerages-anticipate-cytomx-therapeutics-ctmx-to-announce-0-30-earnings-per-share.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.